FDA OKs Celgene’s Rare-Disease Anemia DrugBy
The US Food and Drug Administration (FDA) has approved Celgene’s and Acceleron’s Pharma Reblozyl (luspatercept-aamt) for treating anemia in adult patients with beta thalassemia, a rare blood disorder, who require red-blood-cell transfusions. Acceleron is a biopharmaceutical company focused on rare diseases.
Reblozyl is an erythroid maturation agent that promotes late-stage red-blood-cell maturation. Acceleron and Celgene are co-promoting Reblozyl in North America for treating anemia in adult patients with beta thalassemia, a rare, inherited blood disorder caused by a genetic defect in hemoglobin, who require red-blood-cell transfusions. The companies are also developing luspatercept for treating chronic anemia in myelodysplastic syndromes and myelofibrosis.
Reblozyl is anticipated to be available one week following the FDA approval on November 8, 2019.